Your institution may have access to this item. Find your institution then sign in to continue.
Title
AHEAD 3‐45 study design: A global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer's disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial): Clinical trial design and implementation